Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Definition of systemic sclerosis
- Organs/systems involved in SSc
- The diagnostic process in SSc patients (1)
- ACR/EULAR 2013 classification criteria
- Pitfalls of using classification criteria for diagnosis
- Internal organ involvement & SSc sine scleroderma
- ANA-negative systemic sclerosis
- Early diagnosis of systemic sclerosis
- Raynaud's phenomenon
- Diagnostic approach for isolated RP
- Disease marker autoantibodies
- Capillaroscopic changes
- SSc outcomes in patients with RP
- Early SSc analysis of disease course
- Serum levels of collagen metabolites
- The diagnostic process in SSc patients (2)
- Two-subset classification
- Diffuse cutaneous SSc
- Limited cutaneoud SSc
- Risk assessment of organ manifestations in SSc
- Marker antinuclear antibodies in SSc
- Clinical limitations of commercial antibody testing
- The diagnostic process in SSc patients (3)
- Core variables for defining organ involvement
- Further necessary investigations
- Nailfold videocapillaroscopy
- Extent of HR lung CT predicts mortality
- Tissue doppler echocardiography
- When should RH CAT be performed?
- Haemodynamic definitions of PH
- Diagnostic dilemmas in CTD-PAH
- Morphological features of PVOD
- Routine laboratory analyses
- Assessment of skin involvement
- Assessment of vascular involvement
- Assessment of gut involvement
- Assessment of lung involvement
- Assessment of heart involvement
- Assessment of kidney involvement
- Assessment of articular, joint & muscle involvement
- Assessment of quality of life
- Scleroderma HAQ
- The diagnostic process in SSc patients (4)
- Activity vs. damage
- Factors stopping easy definition of disease activity
- Pathology of activity and damage in SSc
- EScSG whole series index
- Validation steps
- Revised EUSTAR activty index
- The diagnostic process in SSc patients (5)
- Negative prognostic factors
- Clinical prediction of 5-year survival
- Predictors of low survival
- Revised preliminary severity scale
- Thank you
Topics Covered
- Definition of systemic sclerosis
- Aspects of the diagnostic process
- Pitfalls of using classification criteria for diagnosis
- Early diagnosis of systemic sclerosis
- Disease marker autoantibodies
- Outcomes in patients with Raynaud’s Phenomenon
- Haemodynamic definitions of PH
- Assessment of distinct organ involvement and of quality of life
- Pathology of activity and damage in SSc
- Prediction of prognosis and its factors
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Valentini, G. (2018, October 31). Novel aspects of systemic sclerosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 14, 2024, from https://doi.org/10.69645/TDGD3766.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Gabriele Valentini has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Immunology & Inflammation
Transcript
Please wait while the transcript is being prepared...
0:00
The first slide is just to introduce myself.
I am Gabriele Valentini and work
at the University Degli Studi della Campania Luigi Vanvitelli,
where I am professor of Rheumatology and the Chief of the Rheumatology Unit.
0:24
The next slide shows the nosography of systemic sclerosis.
It is a multi-system
autoimmune rheumatic disease that involves the skin and distinct internal organs.
From a morphological point of view,
it is characterized by three main features: interstitial fibrosis;
microangiopathy, that can be obliterative or dilatative or both;
and proliferative small artery disease.
1:05
The next slide depicts the prevalences of
each organ system involving systemic sclerosis.
All the patients present with vascular disease.
The main manifestation of which is represented by Raynaud's phenomenon.
Ninety-three percent of them present with skin sclerosis;
90 percent with the gastrointestinal system manifestations -
mainly esophageal involvement;
70 percent [present] with lung disease -
either interstitial lung disease or pulmonary arterial hypertension;
50 percent with heart disease;
40 percent with the locomotor system disease;
and from three to 15 percent and a median of nine percent, scleroderma renal crisis.